

## ASX ANNOUNCEMENT

ASX: 1AI | 2 April 2026

### Algorae Pharmaceuticals Ltd Raises \$3.9m

Algorae Pharmaceuticals Ltd (ASX: 1AI) ("Algorae" or "the Company") is pleased to announce that it has successfully raised **\$3,988,183** (before costs), comprising 242,998,655 shares issued on the exercise of 1AIO listed options between November 2025 and March 2026, and 89,350,001 shortfall placement shares to sophisticated, long-term shareholders of the Company at \$0.012 (1.2 cents) per share under the Company's available placement capacity under ASX Listing Rule 7.1. The issue price of the placement shares represents a 25% discount to the last trading price of \$0.016 and 30.64% discount to the 5-day Volume Weighted Average Price of \$0.0173.

Net proceeds will significantly strengthen the Company's working capital position as it scales its commercial portfolio under AlgoraeRx and advances its R&D pipeline under AlgoraeOS, both key pillars of Algorae's growth strategy.

#### Financial Position

Following completion of the capital raising initiative, the Company holds a proforma cash balance of approximately **\$5,560,000**, alongside a \$3,000,000 receivables-based debt facility with ScotPac (announced 21 January 2026).

The strengthened balance sheet positions Algorae to capitalise on the commercial and scientific momentum generated over recent months. The Company looks forward to providing further updates as these initiatives progress.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd**

**END.**


#### Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: [inquiries@algoraepharma.com](mailto:inquiries@algoraepharma.com)

For personal use only



## About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design. In parallel, Algorae operates a commercialisation business, AlgoraeRx, which sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. Algorae collaborates with research institutions and industry partners to translate AI-predicted therapies and expand patient access to high-quality medicines. For more information visit [www.algoraepharma.com](http://www.algoraepharma.com) or follow @algoraepharma on X or LinkedIn.

## Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.